Cargando…

Quality of advertisements for prescription drugs in family practice medical journals published in Australia, Canada and the USA with different regulatory controls: a cross-sectional study

OBJECTIVE: To assess if different forms of regulation lead to differences in the quality of journal advertisements. DESIGN: Cross-sectional study. PARTICIPANTS: Thirty advertisements from family practice journals published from 2013 to 2015 were extracted for three countries with distinct regulatory...

Descripción completa

Detalles Bibliográficos
Autores principales: Diep, Dion, Mosleh-Shirazi, Abnoos, Lexchin, Joel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7371147/
https://www.ncbi.nlm.nih.gov/pubmed/32690502
http://dx.doi.org/10.1136/bmjopen-2019-034993
_version_ 1783561089254948864
author Diep, Dion
Mosleh-Shirazi, Abnoos
Lexchin, Joel
author_facet Diep, Dion
Mosleh-Shirazi, Abnoos
Lexchin, Joel
author_sort Diep, Dion
collection PubMed
description OBJECTIVE: To assess if different forms of regulation lead to differences in the quality of journal advertisements. DESIGN: Cross-sectional study. PARTICIPANTS: Thirty advertisements from family practice journals published from 2013 to 2015 were extracted for three countries with distinct regulatory pharmaceutical promotion systems: Australia, Canada and the USA. PRIMARY AND SECONDARY OUTCOME MEASURES: Advertisements under each regulatory system were compared concerning three domains: information included in the advertisement, references to scientific evidence and pictorial appeals and portrayals. An overall ranking for advertisement quality among countries was determined using the first two domains as the information assessed has been associated with more appropriate prescribing. RESULTS: Advertisements varied significantly for number of claims with quantitative benefit (Australia: 0.0 (0.0–3.0); Canada: 0.0 (0.0–5.0); USA: 1.0 (0.0–6.0); p=0.01); statistical method used in reporting benefit (relative risk reduction, absolute risk reduction and number needed to treat; Australia: 6.7%, n=2; Canada: 10.0%, n=3; USA: 36.6%, n=11; p=0.02); mention of adverse effects, warnings or contraindications (Australia: 13.3%, n=4; Canada: 23.3%, n=7; USA: 53.3%, n=16; p=0.002); equal prominence between safety and benefit information (Australia: 25.0%, n=1; Canada: 28.6%, n=2; USA: 75.0%, n=12; p=0.04); and methodological quality of references score (Australia: 0.4150 (0.25–0.70); Canada: 0.25 (0.00–0.63); USA: 0.25 (0.00–0.75); p<0.001). The USA ranked first, Canada second and Australia third for overall quality of journal advertisements. Significant differences for humour appeals (Australia: 3.3%, n=1; Canada: 13.3%, n=4; USA: 26.7%, n=8; p=0.04), positive emotional appeals (Australia: 26.7%, n=8; Canada: 60.0%, n=18; USA: 50.0%, n=15; p=0.03), social approval portrayals (Australia: 0.0%, n=0; Canada: 0.0%, n=0; USA: 10.0%, n=3; p=0.04) and lifestyle or work portrayals (Australia: 43.3%, n=13; Canada: 50.0%, n=15; USA: 76.7%, n=23; p=0.02) were found among countries. CONCLUSIONS: Different regulatory systems influence journal advertisement quality concerning all measured domains. However, differences may also be attributed to other regulatory, legal, cultural or health system factors unique to each country.
format Online
Article
Text
id pubmed-7371147
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-73711472020-07-22 Quality of advertisements for prescription drugs in family practice medical journals published in Australia, Canada and the USA with different regulatory controls: a cross-sectional study Diep, Dion Mosleh-Shirazi, Abnoos Lexchin, Joel BMJ Open Health Policy OBJECTIVE: To assess if different forms of regulation lead to differences in the quality of journal advertisements. DESIGN: Cross-sectional study. PARTICIPANTS: Thirty advertisements from family practice journals published from 2013 to 2015 were extracted for three countries with distinct regulatory pharmaceutical promotion systems: Australia, Canada and the USA. PRIMARY AND SECONDARY OUTCOME MEASURES: Advertisements under each regulatory system were compared concerning three domains: information included in the advertisement, references to scientific evidence and pictorial appeals and portrayals. An overall ranking for advertisement quality among countries was determined using the first two domains as the information assessed has been associated with more appropriate prescribing. RESULTS: Advertisements varied significantly for number of claims with quantitative benefit (Australia: 0.0 (0.0–3.0); Canada: 0.0 (0.0–5.0); USA: 1.0 (0.0–6.0); p=0.01); statistical method used in reporting benefit (relative risk reduction, absolute risk reduction and number needed to treat; Australia: 6.7%, n=2; Canada: 10.0%, n=3; USA: 36.6%, n=11; p=0.02); mention of adverse effects, warnings or contraindications (Australia: 13.3%, n=4; Canada: 23.3%, n=7; USA: 53.3%, n=16; p=0.002); equal prominence between safety and benefit information (Australia: 25.0%, n=1; Canada: 28.6%, n=2; USA: 75.0%, n=12; p=0.04); and methodological quality of references score (Australia: 0.4150 (0.25–0.70); Canada: 0.25 (0.00–0.63); USA: 0.25 (0.00–0.75); p<0.001). The USA ranked first, Canada second and Australia third for overall quality of journal advertisements. Significant differences for humour appeals (Australia: 3.3%, n=1; Canada: 13.3%, n=4; USA: 26.7%, n=8; p=0.04), positive emotional appeals (Australia: 26.7%, n=8; Canada: 60.0%, n=18; USA: 50.0%, n=15; p=0.03), social approval portrayals (Australia: 0.0%, n=0; Canada: 0.0%, n=0; USA: 10.0%, n=3; p=0.04) and lifestyle or work portrayals (Australia: 43.3%, n=13; Canada: 50.0%, n=15; USA: 76.7%, n=23; p=0.02) were found among countries. CONCLUSIONS: Different regulatory systems influence journal advertisement quality concerning all measured domains. However, differences may also be attributed to other regulatory, legal, cultural or health system factors unique to each country. BMJ Publishing Group 2020-07-19 /pmc/articles/PMC7371147/ /pubmed/32690502 http://dx.doi.org/10.1136/bmjopen-2019-034993 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Health Policy
Diep, Dion
Mosleh-Shirazi, Abnoos
Lexchin, Joel
Quality of advertisements for prescription drugs in family practice medical journals published in Australia, Canada and the USA with different regulatory controls: a cross-sectional study
title Quality of advertisements for prescription drugs in family practice medical journals published in Australia, Canada and the USA with different regulatory controls: a cross-sectional study
title_full Quality of advertisements for prescription drugs in family practice medical journals published in Australia, Canada and the USA with different regulatory controls: a cross-sectional study
title_fullStr Quality of advertisements for prescription drugs in family practice medical journals published in Australia, Canada and the USA with different regulatory controls: a cross-sectional study
title_full_unstemmed Quality of advertisements for prescription drugs in family practice medical journals published in Australia, Canada and the USA with different regulatory controls: a cross-sectional study
title_short Quality of advertisements for prescription drugs in family practice medical journals published in Australia, Canada and the USA with different regulatory controls: a cross-sectional study
title_sort quality of advertisements for prescription drugs in family practice medical journals published in australia, canada and the usa with different regulatory controls: a cross-sectional study
topic Health Policy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7371147/
https://www.ncbi.nlm.nih.gov/pubmed/32690502
http://dx.doi.org/10.1136/bmjopen-2019-034993
work_keys_str_mv AT diepdion qualityofadvertisementsforprescriptiondrugsinfamilypracticemedicaljournalspublishedinaustraliacanadaandtheusawithdifferentregulatorycontrolsacrosssectionalstudy
AT moslehshiraziabnoos qualityofadvertisementsforprescriptiondrugsinfamilypracticemedicaljournalspublishedinaustraliacanadaandtheusawithdifferentregulatorycontrolsacrosssectionalstudy
AT lexchinjoel qualityofadvertisementsforprescriptiondrugsinfamilypracticemedicaljournalspublishedinaustraliacanadaandtheusawithdifferentregulatorycontrolsacrosssectionalstudy